184
Participants
Start Date
June 30, 2014
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
Bococizumab (PF-04950615;RN316)
150 mg every 2 weeks by subcutaneous injection for 24 weeks
Atorvastatin
Atorvastatin PO QD
Placebo for Bococizumab (PF-04950615;RN316)
150 mg every 2 weeks by subcutaneous injection for 24 weeks
Placebo for atorvastatin
PO QD
Clinical and Translational Research Center, Hospital of the University of Pennsylvania, Philadelphia
Perelman Center for Advanced Medicine, Philadelphia
Berks Cardiologists, Ltd., Wyomissing
PMG Research of Wilmington, LLC, Wilmington
St. Johns Center for Clinical Research, Ponte Vedra
Progressive Medical Research, Port Orange
Cardiovascular Research Center Of South Florida, Miami
Watson Clinic Center for Research, Inc. (for Drug Shipment only), Lakeland
PMG Research of Bristol, Bristol
PMG Research of Knoxville, LLC, Knoxville
Dayton Heart Center, Dayton
The Iowa Clinic, PC, West Des Moines
The University of Iowa - College of Public Health - Preventive Intervention Center, Iowa City
Allina Health System, dba Abbott Northwestern Hospital, Minneapolis
Minneapolis Heart Institute Foundation, Minneapolis
Advocate Medical Group Midwest Heart Specialists, Park Ridge
NorthShore University HealthSystem - Evanston Hospital, Evanston
Health Care Centers of Illinois Mokena Medical Commons, Mokena
Advocate Medical Group Cardiology, Normal
Prairie Education & Research Cooperative (Administrative), Springfield
Prairie Heart Institute, Springfield
St. John's Hospital, Springfield
University of Kansas Medical Center, Kansas City
Crescent City Clinical Research Center, Metairie
Office of Michelle Zaniewski MD., PA., Houston
Creekside Endocrine Associates, PC, Denver
Utah Cardiology, P.C., Layton
Aspen Clinical Research LLC, Orem
East-West Medical Research Institute, Honolulu
Bridgeport Hospital, Bridgeport
San Antonio Military Medical Center, Fort Sam Houston
The Medical Arts Health Research Group, Kelowna
Corunna Medical Research Centre, Corunna
The Office of Dr. James Cha, Oshawa
Kawartha Cardiology Clinical Trials, Peterborough
Devonshire Clinical Research Inc., Woodstock
Ecogene-21, Chicoutimi
Omnispec clinical research inc., Mirabel
Clinique des maladies lipidiques de Quebec, Québec
Diex Research Sherbrooke Inc., Sherbrooke
Lead Sponsor
Pfizer
INDUSTRY